Deciphering the Role of Oroxylin A in Liver Fibrosis
Drug Design, Development and Therapy · 2025
DOI: 10.2147/dddt.s530387 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Drug Design, Development and Therapy, 2025. Verfasst von Siqing Wang und 6 weiteren Autor:innen. Beteiligte Einrichtung: The First Clinical Medical College of Shandong University of Traditional Chinese Medicine, Jinan, Shandong, People's Republic of China. Hauptthemen laut MEDLINE: Liver Cirrhosis, Flavonoids. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 115 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Liver fibrosis is a dynamic and complex process characterized by the excessive accumulation of extracellular matrix (ECM) components, driven by a heterogeneous population of hepatic myofibroblasts (MFs). Current treatments for liver fibrosis primarily include pharmacological interventions such as antiviral and anti-fibrotic therapies, alongside lifestyle modifications, including dietary changes and alcohol abstinence. However, the therapeutic outcomes remain suboptimal. Existing anti-fibrotic medications are unable to fully reverse liver fibrosis, particularly in its advanced stages, and some drugs may even induce adverse effects. Recently, the challenge of combating liver fibrosis has attracted increasing attention from both the academic community and the general public, leading to extensive research efforts and several significant discoveries. Hepatocyte senescence, an irreversible and inevitable process, plays a crucial role in the onset and progression of various liver diseases. It serves as a key regulatory factor in the development of liver fibrosis, exerting a considerable impact on its progression. Senescent hepatocytes secrete the senescence-associated secretory phenotype (SASP), which interacts with hepatic stellate cells (HSCs), promoting their transformation into MFs. Additionally, SASP fosters a cellular microenvironment conducive to the advancement of hepatic fibrosis, thereby accelerating its progression. This review comprehensively examines the natural flavonoid compound Oroxylin A (OA), which regulates hepatocyte senescence in the context of liver fibrosis. The paper also discusses the current research landscape, trends, and critical challenges related to hepatocyte senescence in liver fibrosis, along with the mechanisms through which OA influences hepatocyte senescence, either promoting or delaying its onset.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The First Clinical Medical College of Shandong University of Traditional Chinese Medicine, Jinan, Shandong, People's Republic of China.
- School of Clinical and Basic Medicine, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, Shandong, People's Republic of China.
- Department of Gastroenterology, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, People's Republic of China.
- The Department of Traditional Chinese Medicine Ophthalmology, The First Affiliated Hospital of Shandong First Medical University, Jinan, Shandong, People's Republic of China.
- Department of General Surgery, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, Shandong, People's Republic of China.
ORCID-Profile: Siqing Wang, Jian Sun, Shuhong Huang
Zitieren
APA
Wang, S., Wu, J., Sun, J., Chen, W., Tian, Z., Huang, S., & Wang, M. (2025). Deciphering the Role of Oroxylin A in Liver Fibrosis. Drug Design, Development and Therapy. https://doi.org/10.2147/dddt.s530387
Vancouver
Wang S, Wu J, Sun J, Chen W, Tian Z, Huang S, et al. Deciphering the Role of Oroxylin A in Liver Fibrosis. Drug Design, Development and Therapy. 2025. doi:10.2147/dddt.s530387
BibTeX
@article{Wang2025,
author = {Wang, Siqing and Wu, Jing and Sun, Jian and Chen, Wei and Tian, Zhaochun and Huang, Shuhong and Wang, Meng},
title = {Deciphering the Role of Oroxylin A in Liver Fibrosis},
journal = {Drug Design, Development and Therapy},
year = {2025},
doi = {10.2147/dddt.s530387}
}
EUVIMED